Insulin Efsitora Alfa + Insulin Degludec
Phase 3Completed 2 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes
Conditions
Type 1 Diabetes, Diabetes
Trial Timeline
Aug 12, 2022 → May 7, 2024
NCT ID
NCT05463744About Insulin Efsitora Alfa + Insulin Degludec
Insulin Efsitora Alfa + Insulin Degludec is a phase 3 stage product being developed by Eli Lilly for Type 1 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT05463744. Target conditions include Type 1 Diabetes, Diabetes.
What happened to similar drugs?
20 of 20 similar drugs in Type 1 Diabetes were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05463744 | Phase 3 | Completed |
| NCT05362058 | Phase 3 | Completed |
| NCT05275400 | Phase 3 | Completed |
Competing Products
20 competing products in Type 1 Diabetes